These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 35111680)

  • 1. Prospects of Immunotherapy for Triple-Negative Breast Cancer.
    Qiu D; Zhang G; Yan X; Xiao X; Ma X; Lin S; Wu J; Li X; Wang W; Liu J; Ma Y; Ma M
    Front Oncol; 2021; 11():797092. PubMed ID: 35111680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
    Yang T; Li W; Huang T; Zhou J
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
    Rahman A; Janic B; Rahman T; Singh H; Ali H; Rattan R; Kazi M; Ali MM
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
    Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
    Front Oncol; 2022; 12():779786. PubMed ID: 35646659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
    Chen X; Feng L; Huang Y; Wu Y; Xie N
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
    Miyashita M; Ishida T
    Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.
    Yi H; Li Y; Tan Y; Fu S; Tang F; Deng X
    Front Oncol; 2021; 11():648139. PubMed ID: 34094935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
    Mediratta K; El-Sahli S; D'Costa V; Wang L
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
    Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
    Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational combination of immunotherapy for triple negative breast cancer treatment.
    Li CW; Lim SO; Hsu JL; Hung MC
    Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.